The combination of ADT and radiotherapy can provide quick benefits in patients with intermediate- or high-risk localized PCa. Dr. Yerram elucidates the evolving landscape of focal therapy for prostate cancer, emphasizing its ease of adoption. Dr. Yerram describes his post-HIFU surveillance protocol: regular PSA checks, MRI, and biopsies at defined intervals. Dr. Yerram explains the use of HIFU and cryotherapy as primary focal therapy modalities, emphasizing a few treatment options. Dr. Yerram explains how advances in focal therapy technologies over the past decade have driven increased use and acceptance. Dr. Hong reviews relevant key findings from clinical trials for oligometastatic disease. Dr. Hong reviews the criteria used to determine which patients may benefit from MDT. Dr. Chu highlights how PSMA PET is transforming perioperative prostate cancer care, including improving surgical precision. Dr. Tagawa compares the use of PSMA-targeted antibodies to other treatment approaches such as radioligand therapy. Apalutamide can boost rPFS and OS in patients with mHSPC when diagnosed via conventional imaging. Dr. Kishan reviews current evidence supporting the use of PSMA RLT in patients with oligometastatic disease. 177Lu vipivotide tetraxetan is the only PSMA-targeted agent to significantly improve rPFS with a tolerable safety profile. Dr. Antonarakis discusses the differences between PARP1 mRNA expression and other biomarkers used for risk stratification. Dr. Morris discusses trials and rationale behind using PSMA therapy earlier in prostate cancer treatment. Dr. Hope evaluates PSMA PET vs SPECT imaging for tracking therapy response in prostate cancer. Dr. Fendler reviews a multi-center study that used prognostic nomograms to risk-stratify patients based on OS. Dr. Hofman outlines promising PSMA combination therapies and emerging trials aiming to improve prostate cancer outcomes. Dr. Calais provides an overview of this year's PSMA and Beyond conference agenda. Dr. Emmett discusses the Co-PSMA trial, comparing ⁶⁴Cu-SAR-bisPSMA and ⁶⁸Ga-PSMA-11 for detecting prostate cancer ... Dr. Tran discusses the benefits of the Decipher score as well as how stratified patients respond differently.